About gri bio inc - GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.
GRI At a Glance
GRI Bio, Inc.
2223 Avenida De La Playa
La Jolla, California 92037
| Phone | 1-619-400-1170 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -8,207,000.00 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
GRI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.835 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.283 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.051 |
GRI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,051,750.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GRI Liquidity
| Current Ratio | 3.432 |
| Quick Ratio | 3.432 |
| Cash Ratio | 3.073 |
GRI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -188.775 |
| Return on Equity | -382.522 |
| Return on Total Capital | -197.711 |
| Return on Invested Capital | -376.295 |
GRI Capital Structure
| Total Debt to Total Equity | 2.951 |
| Total Debt to Total Capital | 2.867 |
| Total Debt to Total Assets | 2.074 |
| Long-Term Debt to Equity | 1.761 |
| Long-Term Debt to Total Capital | 1.71 |